Orion Biotechnology acquires patent portfolio for potent CCR5 chemokine antagonist
OTTAWA, Sept. 06, 2018 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its subsidiary, Orion Biotechnology Switzerland